Compare uniQure N.V. Ordinary Shares (QURE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Zoetis Inc — how do they compare? uniQure N.V. Ordinary Shares trades at $21.53 (market cap $1.45B), while Zoetis Inc trades at $76.19 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 21.5× uniQure N.V. Ordinary Shares's market cap, and Zoetis Inc pays a 2.82% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Zoetis Inc for 71 Days on average.
| QURE | ZTS | |
|---|---|---|
Market Cap | $1.45B | $31.11B |
Volume | 3,323,243 | 2,515,954 |
Sector | Health | Health |
52-Week High | $70.59 | $147.53 |
52-Week Low | $9.03 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $707.46M | $38.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.
ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
